Top

Published in:

01-05-2020 | Glaucoma | Original Paper

Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%

Authors: Yi-Hsing Chen, Raz Gepstein, Lazha Sharief, Hsiao-Jung Tseng, Ruoxin Wei, Xiaozhe Zhang, Sue Lightman, Oren Tomkins-Netzer

Published in: International Ophthalmology | Issue 5/2020

Abstract

Purpose

To investigate the efficacy and safety of 1% rimexolone ophthalmic suspension in children with chronic anterior uveitis under real-life conditions in a tertiary center.

Methods

This is a retrospective longitudinal study. Medical records were analyzed at baseline, 1, 3, 6 and 12 months before and after switching to rimexolone for best-corrected visual acuity (BCVA), oral steroid use, number of flares, IOP and anti-glaucoma management.

Results

Twenty-four patients (41 eyes) diagnosed with either anterior uveitis (n = 25, 60.0%) or panuveitis (n = 16, 40%) were enrolled. The mean age was 10.5 years (4–16 years). The number of patients requiring oral prednisolone reduced from 8 patients (32.0%) at baseline to 3 patients (20.0%) at 12 months (P < 0.001). Following baseline, the median number of uveitis flares reduced from 2.0 (inter-quartile range (IQR) 1.0–2.75) to 1.0 (IQR 0.0–1.0) compared to the 12 months before baseline (P < 0.001). The mean IOP reduced from baseline (22.0 ± 7.3 mmHg) to 1 month (18.8 ± 8.7 mmHg, P = 0.01) and remained stable up to 12 months (15.9 ± 5.0 mmHg, P < 0.001). Average BCVA, dose of oral prednisolone and anti-glaucoma treatments did not change compared to the baseline. The development for IOP ≥ 30 mmHg was associated with a known corticosteroid response [odds ratio (OR) 6.8, P = 0.003] and a dose > 7.5 mg/day oral prednisolone (OR 4.4, P = 0.033).

Conclusions

Rimexolone 1% ophthalmic suspension is an effective and safe topical steroid for pediatric anterior uveitis.

Pascolini D, Mariotti SP (2012) Global estimates of visual impairment: 2010. Br J Ophthalmol 96(5):614–618. https://doi.org/10.1136/bjophthalmol-2011-300539 PubMedCrossRef

Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI (2004) Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 88(9):1159–1162. https://doi.org/10.1136/bjo.2003.037226 PubMedPubMedCentralCrossRef

Darrell RW, Wagener HP, Kurland LT (1962) Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol (Chicago, Ill: 1960) 68:502–514CrossRef

Suttorp-Schulten MS, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80(9):844–848PubMedPubMedCentralCrossRef

BenEzra D, Cohen E, Maftzir G (2005) Uveitis in children and adolescents. Br J Ophthalmol 89(4):444–448. https://doi.org/10.1136/bjo.2004.050609 PubMedPubMedCentralCrossRef

Tomkins-Netzer O, Talat L, Bar A, Lula A, Taylor SR, Joshi L, Lightman S (2014) Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology 121(12):2387–2392. https://doi.org/10.1016/j.ophtha.2014.07.007 PubMedCrossRef

Edelsten C, Reddy MA, Stanford MR, Graham EM (2003) Visual loss associated with pediatric uveitis in english primary and referral centers. Am J Ophthalmol 135(5):676–680PubMedCrossRef

Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, Tessler HH, Nussenblatt RB, Rosenbaum JT, Reed GF, Vitale S, Smith JR, Goldstein DA (2009) Epidemiology and course of disease in childhood uveitis. Ophthalmology 116(8):1544–1551. https://doi.org/10.1016/j.ophtha.2009.05.002 PubMedPubMedCentralCrossRef

Foster CS, Alter G, DeBarge LR, Raizman MB, Crabb JL, Santos CI, Feiler LS, Friedlaender MH (1996) Efficacy and safety of rimexolone 1% ophthalmic suspension vs 1% prednisolone acetate in the treatment of uveitis. Am J Ophthalmol 122(2):171–182PubMedCrossRef

10.

Kothari S, Foster CS, Pistilli M, Liesegang TL, Daniel E, Sen HN, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Lawrence SD, Kempen JH (2015) The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. Ophthalmology 122(10):1987–2001. https://doi.org/10.1016/j.ophtha.2015.06.041 PubMedPubMedCentralCrossRef

11.

Thorne JE, Woreta FA, Dunn JP, Jabs DA (2010) Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 117(7):1436–1441. https://doi.org/10.1016/j.ophtha.2009.12.003 PubMedPubMedCentralCrossRef

12.

Sallam A, Sheth HG, Habot-Wilner Z, Lightman S (2009) Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Am J Ophthalmol 148(2):207–213 e201. https://doi.org/10.1016/j.ajo.2009.02.032 PubMedCrossRef

13.

Armaly MF (1965) Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol 4:187–197PubMed

14.

Becker B (1965) Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 4:198–205PubMed

15.

Razeghinejad MR, Myers JS, Katz LJ (2011) Latrogenic glaucoma secondary to medications. Am J Med 124(1):20–25. https://doi.org/10.1016/j.amjmed.2010.08.011 PubMedCrossRef

16.

Kwok AK, Lam DS, Ng JS, Fan DS, Chew SJ, Tso MO (1997) Ocular-hypertensive response to topical steroids in children. Ophthalmology 104(12):2112–2116PubMedCrossRef

17.

Assil KK, Massry G, Lehmann R, Fox K, Stewart R (1997) Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Surg 23(5):750–757PubMedCrossRef

18.

Bron A, Denis P, Hoang-Xuan TC, Boureau-Andrieux C, Crozafon P, Hachet E, Medhorn E, Akingbehin A (1998) The effects of Rimexolone 1% in postoperative inflammation after cataract extraction. A double-masked placebo-controlled study. Eur J Ophthalmol 8(1):16–21PubMedCrossRef

19.

Biswas J, Ganeshbabu TM, Raghavendran SR, Raizada S, Mondkar SV, Madhavan HN (2004) Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis–a randomized triple masked study. Int Ophthalmol 25(3):147–153PubMedCrossRef

20.

Yaylali V, Ozbay D, Tatlipinar S, Yildirim C, Ozden S (2004) Efficacy and safety of rimexolone 1% versus prednisolone acetate 1% in the control of postoperative inflammation following phacoemulsification cataract surgery. Int Ophthalmol 25(1):65–68PubMedCrossRef

21.

Hirneiss C, Neubauer AS, Kampik A, Schonfeld CL (2005) Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction: a prospective, randomized, double-masked study. Graefes Arch Clin Exp Ophthalmol 243(8):768–773. https://doi.org/10.1007/s00417-005-1126-9 PubMedCrossRef

22.

Kavuncu S, Horoz H, Ardagil A, Erbil HH (2008) Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. Int Ophthalmol 28(4):281–285. https://doi.org/10.1007/s10792-007-9131-0 PubMedCrossRef

23.

Vico-Ruiz E, Benitez-Del-Castillo-Sanchez JM, Cuina-Sardina R, Martinez-De-La-Casa JM, Garcia-Sanchez J (2009) 0.1% dexamathasone and 1% rimexolone. A comparative study in the postoperative treatment after cataract extraction. Arch Soc Esp Oftalmol 84(6):299–304PubMedCrossRef

24.

Arellanes-Garcia L, Padilla-Aguilar G, Navarro-Lopez P, Espinoza-Martinez C (2005) Efficacy of prednisolone and rimexolone in HLA-B27 positive patients with acute anterior uveitis. Gac Med Mex 141(5):363–366PubMed

25.

Fan DS, Yu CB, Chiu TY, Wong CY, Ng JS, Pang CP, Lam DS (2003) Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Arch Ophthalmol (Chicago, Ill : 1960) 121(12):1716–1721. https://doi.org/10.1001/archopht.121.12.1716 CrossRef

26.

Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516PubMedCrossRef

27.

Al Hanaineh AT, Hassanein DH, Abdelbaky SH, El Zawahry OM (2018) Steroid-induced ocular hypertension in the pediatric age group. Eur J Ophthalmol 28(4):372–377. https://doi.org/10.1177/1120672118757434 PubMedCrossRef

28.

Luchtman DW, Ellwardt E, Larochelle C, Zipp F (2014) IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: Current and future developments. Cytokine Growth Factor Rev 25(4):403–413. https://doi.org/10.1016/j.cytogfr.2014.07.013 PubMedCrossRef

29.

Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A (2017) Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis: post hoc analyses from the VISUAL-1 and VISUAL-2 trials. Ophthalmology 124(12):1799–1807. https://doi.org/10.1016/j.ophtha.2017.06.017 PubMedCrossRef

30.

Daniel E, Pistilli M, Kothari S, Khachatryan N, Kacmaz RO, Gangaputra SS, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Bhatt NP, Kempen JH (2017) Risk of ocular hypertension in adults with noninfectious uveitis. Ophthalmology 124(8):1196–1208. https://doi.org/10.1016/j.ophtha.2017.03.041 PubMedPubMedCentralCrossRef

31.

Fox PK, Lewis AJ, Rae RM, Sim AW, Woods GF (1980) The biological properties of Org 6216, a new type of steroid with a selective local anti-inflammatory action. Arzneimittelforschung 30(1):55–59PubMed

32.

Spies CM, Gaber T, Hahne M, Naumann L, Tripmacher R, Schellmann S, Stahn C, Burmester GR, Radbruch A, Buttgereit F (2010) Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. Immunol Lett 131(1):24–32. https://doi.org/10.1016/j.imlet.2010.03.009 PubMedCrossRef

33.

Lowenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, van Deventer SJ, Hommes DW (2006) Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 7(10):1023–1029. https://doi.org/10.1038/sj.embor.7400775 PubMedPubMedCentralCrossRef

34.

Pleyer U, Ursell PG, Rama P (2013) Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther 2(2):55–72. https://doi.org/10.1007/s40123-013-0020-5 PubMedPubMedCentralCrossRef

Title: Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%
Authors: Yi-Hsing Chen
Raz Gepstein
Lazha Sharief
Hsiao-Jung Tseng
Ruoxin Wei
Xiaozhe Zhang
Sue Lightman
Oren Tomkins-Netzer
Publication date: 01-05-2020
Publisher: Springer Netherlands
Keywords: Glaucoma
Uveitis
Prednisolone
Published in: International Ophthalmology / Issue 5/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-020-01358-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Outcome and risk of ocular complications of managing children with chronic anterior uveitis with topical rimexolone 1%

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2020

Intense pulse light therapy treatment for refractory dry eye disease due to meibomian gland dysfunction

Foveal avascular zone and vessel density in children with attention deficit hyperactivity disorder

Protective effects of autophagy inhibitor 3-methyladenine on ischemia–reperfusion-induced retinal injury

Comparison of the effects of 180° and 360° applications of selective laser trabeculoplasty on intraocular pressure and cornea

Colistin resistance in Gram-negative ocular infections: prevalence, clinical outcome and antibiotic susceptibility patterns

Toric intraocular lens in asymmetric astigmatism